Life sciences firm Seer Q2 revenue rises
Overview
Seer Q2 revenue grows 32% yr/yr to $4.1 mln, driven by product sales
Operating expenses decreased 21% due to lower stock-based compensation
Net loss narrowed to $19.4 mln from $22.9 mln in prior year
Outlook
Seer expects 2025 revenue to be $17 mln to $18 mln
Company anticipates 24% revenue growth for full year 2025
Result Drivers
PRODUCT SALES - Revenue growth driven by increased sales of Proteograph instruments and consumable kits
NEW PRODUCT LAUNCHES - Launch of Proteograph ONE assay and SP200 instrument enhanced scalability and efficiency
COLLABORATION - Partnership with Korea University for a large-scale study utilizing Proteograph ONE assay
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| $4.05 mln |
|
Q2 EPS |
| -$0.33 |
|
Q2 Net Income |
| -$19.42 mln |
|
Q2 Gross Margin |
| 52.0% |
|
Q2 Gross Profit |
| $2.11 mln |
|
Q2 Operating Expenses |
| $22.64 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the office equipment peer group is "buy"
Press Release: ID:nGNX7jW8wY
